Tat (Trans-activator of transcription) is implicated in the neuropathogenesis of HIV-1 infection and known to contribute to neuronal damage and learning and memory impairments. However, direct neuroanatomical demonstration of Tat pathobiology is limited. GT-tg bigenic mice with a doxycycline (Dox)-inducible and brain-selective tat gene were used to test the hypothesis that conditional induction of Tat activity in brain can induce gray matter density abnormalities. Ultra high spatial resolution ex vivo magnetic resonance imaging (MRI) combined with a voxel based morphometry (VBM) analysis revealed gray matter density reductions in the sublenticular extended amygdala, the amygdala, the amygdala-hippocampal area, piriform and peri-/entorhinal cortices, and hypothalamus, in Tat-expressing GT-tg mice compared to Dox-treated C57Bl/6J mice. These neuroanatomical abnormalities are consistent with regions expected to be abnormal based on behavioral deficits exhibited by Tat-expressing mice (Carey et al., 2012). These experiments provide the first neuroimaging evidence that conditional Tat protein expression in the GT-tg bigenic mouse model alters brain structure. The findings warrant future studies to further characterize effects of conditional Tat expression on brain structure. Such studies may improve our understanding of the neurological underpinnings of neuroAIDS and the neurodegeneration associated with HIV-1 infection, potentially leading to new treatments.
Introduction
The activity of accessory proteins produced by HIV-1 viral infection of brain, such as Tat (Trans-activator of transcription), may contribute significantly to the persistence of HIV-related neuropathology and subsequent cognitive and psychomotor slowing (Brack-Werner, 1999; Frankel and Young, 1998; Johnston et al., 2001; Power et al., 1998) . It has been suggested that Tat may play a key role in the neurotoxicity and cognitive impairment evident in neuroAIDS (King et al., 2006; Rappaport et al., 1999) . Epidemiological reports indicate that cladespecific variation among HIV-1 strains results in differences in the prevalence of HIV-associated dementia (Ranga et al., 2004) and human neuronal toxicity (Mishra et al., 2008; Rao et al., 2008) . This variation has been linked to mutations within the neurotoxic epitope of the tat gene.
Tat protein is an established inflammatory agent, activating microglia both in vitro and ex vivo (Bokhari et al., 2009; Bruce-Keller et al., 2001 ). Tat-induced neuroinflammation in particular brain regions has also been demonstrated in vivo, specifically in both the cortex and hippocampus of GT-tg bigenic mice (Zou et al., 2007) , the cortex of CX 3 CR 1 GFP/+ mice (Marker et al., 2010) and the striatum of another strain of inducible Tat transgenic mouse (BruceKeller et al., 2008) . In vitro cell culture studies have shown Tat to cause inflammation and excitotoxicity (Aksenova et al., 2005) , which have been correlated with an induction of oxidative stress and astrocytosis (Toborek et al., 2003; Zhou et al., 2004) . These events are thought to impair astrocyte capacity to support neuronal function (Glass et al., 1993; Zhou et al., 2004) , creating a toxic extracellular environment (Aksenov et al., 2001 (Aksenov et al., , 2003 Fitting et al., 2010) . Tatinduced OS also has been associated with neurotoxicity and loss of brain function, and with pyramidal hippocampal neuronal damage (Aksenova et al., 2005; Askenov et al., 2006) . In vitro studies
